Pharmaceutical dosage form for oral administration of a bcl 2 family inhibitor

US9642796B2 · kind B2 · utility

Assignee

• Abb Vie Inc. · US

Inventors

• Claudia Bettina Packhaeuser · Macclesfield, GB
• Norbert Steiger · Lingenfeld, DE
• Bernd Liepold · Dossenheim, DE
• Drazen Kostelac · Münstermaifeld, DE
• Martin Knobloch · Schifferstadt, DE

Key dates

• Filing date: Jun 8, 2010
• Grant date: May 9, 2017
• Expiry date: Oct 14, 2030

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P35/02
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to a pharmaceutical dosage form which comprises a solid dispersion product comprising N-(4-(4-((2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohex-1-en-1-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-((trifluoromethyl)sulfonyl)benzenesulfonamide or a salt, hydrate or solvate thereof, at least one pharmaceutically acceptable polymer, and at least one pharmaceutically acceptable solubilizer. The invention is further directed to processes for preparing the pharmaceutical dosage form and to use of the dosage form for treating proliferative disorders.